This invention relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.
本发明涉及 20,23-二
哌啶基-5-O-mycaminosyl-tylonolide 的溶解和非溶解结晶形式,以及制造这种结晶形式的方法、包含(或衍生自)这种结晶形式的药物、制造包含(或衍生自)这种结晶形式的药物的方法、使用这种结晶形式的治疗方法和包含这种结晶形式的试剂盒。